Form 4: CytomX Therapeutics Director Elaine V. Jones Acquires 38,000 Stock Options

CytomX Therapeutics, Inc. Director Elaine V. Jones acquired 38,000 stock options with an exercise price of $2.82, vesting on the earlier of the first anniversary of the grant date or the 2026 Annual Meeting.

Summary

• Elaine V. Jones, a Director of CytomX Therapeutics, Inc. (CTMX), acquired 38,000 stock options (Right to Buy) for the company's common stock.
• The transaction date for the option grant was June 11, 2025.
• The exercise price for these stock options is $2.82 per share.
• The options are set to vest and become exercisable as to 100% of the total number of shares on the earlier of (i) the first anniversary of the grant date (June 11, 2026) or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders.
• Vesting is contingent upon Elaine V. Jones' continuous service as a director until the vesting date.
• The expiration date for these stock options is June 10, 2035.
• Following this reported transaction, Elaine V. Jones beneficially owns 38,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed positively as it aligns the director's interests with shareholder value and indicates confidence in the company's future.

Positives

• A director, Elaine V. Jones, acquired 38,000 stock options, which can be interpreted as a positive sign of confidence in the company's future performance and aligns her interests with shareholder value.

Negatives

• NA

Risks

• The value of the acquired stock options is directly dependent on the future market price of CytomX Therapeutics, Inc. common stock exceeding the exercise price of $2.82.
• Vesting of the options is contingent upon Elaine V. Jones' continuous service as a director until the specified vesting date.

Future Outlook

The stock options are set to vest on the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service.

Industry Context

This Form 4 filing details an individual insider transaction (stock option grant to a director) and does not provide broader industry context or trends.

Related Party Transactions

• Grant of 38,000 stock options to Elaine V. Jones, a Director of CytomX Therapeutics, Inc., which constitutes a related party transaction as part of director compensation.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholder value, as the options' value increases with the company's stock price. However, future exercise of these options could lead to minor share dilution.

Next Steps

• Vesting of the 38,000 stock options on the earlier of June 11, 2026, or the date of the 2026 Annual Meeting of Stockholders, contingent on continuous service.

Key Dates

Keywords

CytomX Therapeutics, CTMX, SEC Form 4, Stock Options, Insider Trading, Director Compensation, Equity Grant, Beneficial Ownership